Cargando…

C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients

BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallard, Joris, Gagez, Anne-Laure, Baudinet, Cedric, Herbinet, Aline, Maury, Jonathan, Bernard, Pierre Louis, Cartron, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153683/
https://www.ncbi.nlm.nih.gov/pubmed/32300444
http://dx.doi.org/10.14740/jh536
_version_ 1783521695560105984
author Mallard, Joris
Gagez, Anne-Laure
Baudinet, Cedric
Herbinet, Aline
Maury, Jonathan
Bernard, Pierre Louis
Cartron, Guillaume
author_facet Mallard, Joris
Gagez, Anne-Laure
Baudinet, Cedric
Herbinet, Aline
Maury, Jonathan
Bernard, Pierre Louis
Cartron, Guillaume
author_sort Mallard, Joris
collection PubMed
description BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective of this work was to identify risk factor of cachexia in a cohort of patients with hematological malignancies to develop strategies to prevent cachexia and its consequences. METHODS: Clinical and biological parameters were collected before and at the end of the treatment. Quantification of weight loss during cachexia was performed by the method of Martin. Clinical responses to treatment of patients with lymphoma or myeloma were monitored. RESULTS: Thirty-eight percent of the 145 patients enrolled were cachectic at the end of treatment. Classical prognostic disease scores at the time of diagnosis seemed to be not associated with cachexia observed at the end of treatment. Only C-reactive protein (CRP) > 54 mg/L seemed to be a risk factor of cachexia (P = 0.023, odds ratio (OR): 5.94 (1.55 - 39.14), confidence interval (CI): 1.55 - 39.14). Those results were confirmed by bootstrap analysis. CONCLUSION: This study highlights that high CRP level at diagnosis seems to be a risk factor for cachexia during treatment, permitting to identify patients at risk and in future to implement preventive strategies.
format Online
Article
Text
id pubmed-7153683
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-71536832020-04-16 C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients Mallard, Joris Gagez, Anne-Laure Baudinet, Cedric Herbinet, Aline Maury, Jonathan Bernard, Pierre Louis Cartron, Guillaume J Hematol Short Communication BACKGROUND: Cachexia is defined as an involuntary loss of weight, characterized by a loss of skeletal muscle mass with or without fat mass loss. It increases mortality risk and decreases quality of life in patients with lymphoma or myeloma. Early markers of cachexia are not identified. The objective of this work was to identify risk factor of cachexia in a cohort of patients with hematological malignancies to develop strategies to prevent cachexia and its consequences. METHODS: Clinical and biological parameters were collected before and at the end of the treatment. Quantification of weight loss during cachexia was performed by the method of Martin. Clinical responses to treatment of patients with lymphoma or myeloma were monitored. RESULTS: Thirty-eight percent of the 145 patients enrolled were cachectic at the end of treatment. Classical prognostic disease scores at the time of diagnosis seemed to be not associated with cachexia observed at the end of treatment. Only C-reactive protein (CRP) > 54 mg/L seemed to be a risk factor of cachexia (P = 0.023, odds ratio (OR): 5.94 (1.55 - 39.14), confidence interval (CI): 1.55 - 39.14). Those results were confirmed by bootstrap analysis. CONCLUSION: This study highlights that high CRP level at diagnosis seems to be a risk factor for cachexia during treatment, permitting to identify patients at risk and in future to implement preventive strategies. Elmer Press 2019-06 2019-06-30 /pmc/articles/PMC7153683/ /pubmed/32300444 http://dx.doi.org/10.14740/jh536 Text en Copyright 2019, Mallard et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Mallard, Joris
Gagez, Anne-Laure
Baudinet, Cedric
Herbinet, Aline
Maury, Jonathan
Bernard, Pierre Louis
Cartron, Guillaume
C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title_full C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title_fullStr C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title_full_unstemmed C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title_short C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
title_sort c-reactive protein level: a key predictive marker of cachexia in lymphoma and myeloma patients
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153683/
https://www.ncbi.nlm.nih.gov/pubmed/32300444
http://dx.doi.org/10.14740/jh536
work_keys_str_mv AT mallardjoris creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT gagezannelaure creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT baudinetcedric creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT herbinetaline creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT mauryjonathan creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT bernardpierrelouis creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients
AT cartronguillaume creactiveproteinlevelakeypredictivemarkerofcachexiainlymphomaandmyelomapatients